1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke

Bioorg Med Chem Lett. 2008 Jan 1;18(1):409-13. doi: 10.1016/j.bmcl.2007.10.045. Epub 2007 Oct 18.

Abstract

Matrix metalloproteinase-9 (MMP-9) has been implicated in the breakdown of the blood-brain barrier during cerebral ischemia. As a result, inhibition of MMP-9 may have utility as a therapeutic intervention in stroke. Towards this end, we have synthesized a series of 1-hydroxy-2-pyridinones that have excellent in vitro potency in inhibiting MMP-9 in addition to MMP-2. Representative compounds also demonstrate good efficacy in the mouse transient mid-cerebral artery occlusion (tMCAO) model of cerebral ischemia.

MeSH terms

  • Administration, Oral
  • Animals
  • Biological Availability
  • Brain Ischemia / drug therapy*
  • Disease Models, Animal
  • Inhibitory Concentration 50
  • Male
  • Matrix Metalloproteinase Inhibitors*
  • Mice
  • Mice, Inbred C57BL
  • Models, Molecular
  • Protease Inhibitors / chemical synthesis*
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacokinetics
  • Protease Inhibitors / pharmacology
  • Pyridones / chemical synthesis*
  • Pyridones / chemistry
  • Pyridones / pharmacokinetics
  • Pyridones / pharmacology*
  • Structure-Activity Relationship
  • Sulfonamides / chemical synthesis
  • Sulfonamides / chemistry
  • Sulfonamides / pharmacokinetics
  • Sulfonamides / pharmacology
  • Zinc / chemistry
  • Zinc / metabolism

Substances

  • Matrix Metalloproteinase Inhibitors
  • Protease Inhibitors
  • Pyridones
  • Sulfonamides
  • Zinc